Active Stocks
Mon Apr 15 2024 15:59:36
  1. Tata Steel share price
  2. 160.90 -1.59%
  1. ITC share price
  2. 425.90 -0.98%
  1. State Bank Of India share price
  2. 757.75 -1.17%
  1. ICICI Bank share price
  2. 1,078.80 -2.30%
  1. NTPC share price
  2. 361.35 -0.08%
Business News/ News / India/  Bharat Biotech's nasal vaccine showing good results in phase II trial: Chairman
BackBack

Bharat Biotech's nasal vaccine showing good results in phase II trial: Chairman

The adenoviral nasal vaccine BBV154 is first of a kind Covid-19 vaccine to undergo human trials in India.

According to the ministry of science and technology, the phase 1 trial of Bharat Biotech nasal vaccine in healthy volunteers of age groups ranging from 18-60 years was well tolerated (ANI)Premium
According to the ministry of science and technology, the phase 1 trial of Bharat Biotech nasal vaccine in healthy volunteers of age groups ranging from 18-60 years was well tolerated (ANI)

Bharat Biotech has almost completed phase-2 trial for the nasal vaccine and it has shown good results, the pharma company's Chairman and MD said on Saturday.

"We have almost completed phase 2 trials for the nasal vaccine and it has shown good results. This vaccine will help in controlling the transmission of Covid-19 infection," Dr Krishna Ella said.

According to the ministry of science and technology, the phase 1 trial in healthy volunteers of age groups ranging from 18-60 years was well tolerated.

The vaccine has received regulatory approval for second Phase trials in August. The adenoviral intranasal vaccine BBV154 is the first of its kind Covid-19 vaccine to undergo human trials in India.

Trials for the Phase 3 trial will commence after the completion of Phase-2 clinical trials. The intramuscular injection shots usually produces antibodies, but there is still a risk of transmission.

It has raised the possibility that vaccinated people could still catch and spread the virus, even when they don’t know they’re infected. Scientists have proposed that vaccines are given through the nose (intranasally) may be able to block SARS-CoV-2 in both the nasal passages and bloodstream.

Further, Ella lauded the collective efforts of government and citizens as India achieved 100 crore vaccination mark recently.

On the children's vaccine, the chairman said the company is still waiting for a license from drugs regulator DCGI. Hyderabad-based Bharat Biotech has already developed two-dose Covaxin, which has an efficacy of around 78%.

The company is waiting for World Health Organization's (WHO) approval for Covaxin. The technical advisory group at WHO will meet on October 26 to decide on the approval

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 23 Oct 2021, 03:43 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App